Table 2.
Genotype and allele distribution of IL12RB2 genetic variants in the European SSc patients and controls follow-up study (3344 SSc/3848 controls)
| SNP | 1/2 | CTRL |
SSc |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1/1 (n) | 1/2 (n) | 2/2 (n) | MAF | 1/1 (n) | 1/2 (n) | 2/2 (n) | MAF | PMH | OR | 95% CI | PBonf | PBD | ||
| rs924080 | C/T | 0.22 (827) | 0.48 (1807) | 0.29 (1094) | 0.46 | 0.22 (687) | 0.49 (1545) | 0.30 (934) | 0.46 | 0.96 | 1.00 | 0.93–1.07 | 1 | NS |
| rs3790566 | T/C | 0.08 (280) | 0.37 (1334) | 0.55 (1978) | 0.26 | 0.09 (273) | 0.39 (1196) | 0.52 (1617) | 0.28 | 3.35 × 10−2 | 1.09 | 1.01–1.18 | 0.10 | NS |
| rs3790567 | A/G | 0.08 (241) | 0.37 (1169) | 0.56 (1773) | 0.26 | 0.09 (282) | 0.38 (1187) | 0.52 (1616) | 0.28 | 4.84 × 10−3 | 1.12 | 1.04–1.22 | 0.01 | NS |
SSc, systemic sclerosis patients; CTRL, healthy controls; 1/2, minor allele/major allele; MAF, minor allele frequency; PMH, allelic Mantel–Haenszel fixed effects model P-value; OR, odds ratio; 95% CI, 95% confidence interval; PBD, Breslow–Day test P-value; NS, not statistically significant.